All the news Showing 9 of 9 articles from: Treatment in cirrhosisGet an RSS feed of these articles Show All news infohep newsEditors' picks from other sources AbbVie Receives Positive CHMP Opinion for MAVIRET® to Shorten Treatment Duration to Eight Weeks in Genotype 3, Treatment-Naïve Patients with Chronic Hepatitis C and Compensated Cirrhosis AbbVie press release / 04 February 2020 FDA approves treatment for adults and children with all genotypes of hepatitis C and compensated cirrhosis that shortens duration of treatment to eight weeks FDA / 29 September 2019 Early Access to Medicines Scheme (EAMS) Granted to AbbVie’s Investigational Pan-genotypic Regimen for Chronic Hepatitis C in UK AbbVie press release / 10 May 2017 Next-generation HCV treatments should benefit challenging patient groups Digestive Disease Week blog / 23 May 2016 Antiviral therapies give Hepatitis C cirrhosis patients similar life expectancy as general population Manual Items / 05 May 2016 AbbVie receives CHMP positive opinion for VIEKIRAX® + EXVIERA® without ribavirin for the treatment of HCV in GT1b patients with compensated cirrhosis in Europe AbbVie press release / 02 March 2016 U.S. FDA Approves Two Supplemental Indications for Harvoni® in Chronic Hepatitis C Patients With Advanced Liver Disease Gilead press release / 17 February 2016 U.S. FDA Approves Expanded Use of Bristol-Myers Squibb’s Daklinza (daclatasvir) for Additional Challenging-to-treat Patients with Genotype 1 or Genotype 3 Chronic Hepatitis C Bristol-Myers Squibb press release / 08 February 2016 European Commission Approves Daklinza (daclatasvir) for the Treatment of Genotype 1, 3 and 4 Chronic Hepatitis C Patients with HIV Coinfection, Advanced Cirrhosis and Post-liver Transplant Recurrence of HCV Bristol-Myers Squibb press release / 01 February 2016 ← First1Next → Other pages in this section Latest news All the news Hepatitis A Hepatitis B Hepatitis C Hepatitis D Hepatitis E Coronavirus NAFLD Treatment for hepatocellular carcinoma Transmission, epidemiology and prevention Health services, policy and advocacy Social issues Conference news Email bulletin archive